PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.89%
Negative revenue growth while CSIQ stands at 5.82%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-32.38%
Negative gross profit growth while CSIQ is at 1.04%. Joel Greenblatt would examine cost competitiveness or demand decline.
-64.37%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-67.05%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-79.39%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-79.78%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-79.45%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.12%
Share reduction more than 1.5x CSIQ's 6.45%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-1.65%
Reduced diluted shares while CSIQ is at 7.57%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
13.88%
OCF growth of 13.88% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
-323.16%
Negative FCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
6445.22%
10Y revenue/share CAGR at 50-75% of CSIQ's 11486.87%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
5.50%
5Y revenue/share CAGR under 50% of CSIQ's 420.22%. Michael Burry would suspect a significant competitive gap or product weakness.
-46.37%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
1256.12%
OCF/share CAGR of 1256.12% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-52.33%
Negative 5Y OCF/share CAGR while CSIQ is at 1481.86%. Joel Greenblatt would question the firm’s operational model or cost structure.
-89.41%
Negative 3Y OCF/share CAGR while CSIQ stands at 206.36%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
229.38%
Below 50% of CSIQ's 3006.43%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-49.88%
Negative 5Y net income/share CAGR while CSIQ is 128.87%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-88.45%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
-27.56%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-46.96%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.14%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-14.75%
Inventory is declining while CSIQ stands at 4.78%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.71%
Asset growth above 1.5x CSIQ's 0.39%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.92%
BV/share growth above 1.5x CSIQ's 1.11%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
0.30%
We have some new debt while CSIQ reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
13.88%
R&D growth drastically higher vs. CSIQ's 8.96%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
20.40%
SG&A growth well above CSIQ's 25.63%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.